Today, AbbVie announced growth in Humira (adalimumab) sales to $4.15 billion worldwide in the second quarter, a 17.4% increase over the same quarter in 2015.  On June 30^th, AbbVie received FDA approval for a 10^th indication for Humira: non-infectious intermediate, posterior and panuveitis in adults, which can severely impact vision.  According to Abbvie’s press release, Humira is the only approved non-corticosteroid therapy for such patients.